Suppr超能文献

间充质干细胞治疗宫腔粘连的Meta分析:疗效与安全性的综合考量

Meta-analysis of mesenchymal stem cell therapy for intrauterine adhesions: a comprehensive consideration of efficacy and safety.

作者信息

Gao Jiawei, Zhou Xinyue, Jiang Nan, Zhang Yongjuan, Han Jianpeng, Jia Tianyu, Jiang Yanbiao, Ma Xiaoling, Shen Haofei

机构信息

The First Clinical Medical College of Lanzhou University, Lanzhou, China.

Reproductive Medicine Center, The First Hospital of Lanzhou University, Lanzhou, China.

出版信息

Front Bioeng Biotechnol. 2025 Aug 13;13:1619778. doi: 10.3389/fbioe.2025.1619778. eCollection 2025.

Abstract

BACKGROUND

Intrauterine adhesions (IUA), a common gynecological condition, often result from endometrial injury and fibrosis. Traditional therapies like hysteroscopic adhesiolysis and hormone therapy show limited efficacy in endometrial repair and high recurrence rates. Stem cell therapy, particularly using mesenchymal stem cells (MSCs), has emerged as a promising alternative. This meta-analysis evaluates the efficacy and safety of MSCs therapy for IUA.

METHODS

We systematically searched Embase, MEDLINE, and the Cochrane Library up to January 2025. Using random or fixed-effects models, we analyzed outcomes including pregnancy rates, endometrial thickness, menstrual improvement, and safety indicators. Subgroup analyses were performed based on stem cell sources and transplantation methods.

RESULTS

Twelve studies with 233 patients were included. Stem cell therapy significantly improved menstrual outcomes (RR = 34.54, 95%CI: [15.07-79.18]), pregnancy rates (RR = 21.86, 95%CI: [8.60-55.56]), live birth rates (RR = 18.00, 95%CI: [6.67-48.55]), and endometrial thickness (MD = 2.28mm, 95%CI: [1.60-2.96]). Subgroup analyses indicated that adipose-derived (MD = 3.34 mm) and menstrual blood-derived (MD = 3.62 mm) stem cells exhibited the highest efficacy. Safety data indicated mild abdominal pain in 5.15% and abnormal blood indices in 4.29% of patients, with no severe complications.

CONCLUSION

Stem cell therapy may improve the reproductive prognosis of patients with IUA. Autologous adipose or menstrual blood-derived stem cells via local injection are cautiously recommended. Further large-scale RCTs are needed to confirm long-term safety and optimal treatment protocols.

TRIAL REGISTRATION

The review protocol is registered on PROSPERO with registration number CRD42025643871, and no modifications were made to the information provided at registration.

SYSTEMATIC REVIEW REGISTRATION

https://www.crd.york.ac.uk/prospero/, identifier CRD420256438.

摘要

背景

宫腔粘连(IUA)是一种常见的妇科疾病,通常由子宫内膜损伤和纤维化引起。宫腔镜粘连松解术和激素治疗等传统疗法在子宫内膜修复方面疗效有限,且复发率高。干细胞治疗,尤其是使用间充质干细胞(MSCs),已成为一种有前景的替代方法。本荟萃分析评估了MSCs治疗IUA的疗效和安全性。

方法

我们系统检索了截至2025年1月的Embase、MEDLINE和Cochrane图书馆。使用随机或固定效应模型,我们分析了包括妊娠率、子宫内膜厚度、月经改善情况和安全指标等结果。根据干细胞来源和移植方法进行亚组分析。

结果

纳入了12项研究,共233例患者。干细胞治疗显著改善了月经结局(RR = 34.54,95%CI:[15.07 - 79.18])、妊娠率(RR = 21.86,95%CI:[8.60 - 55.56])、活产率(RR = 18.00,95%CI:[6.67 - 48.55])和子宫内膜厚度(MD = 2.28mm,95%CI:[1.60 - 2.96])。亚组分析表明,脂肪来源(MD = 3.34mm)和月经血来源(MD = 3.62mm)的干细胞疗效最高。安全数据显示,5.15%的患者出现轻度腹痛,4.29%的患者血液指标异常,无严重并发症。

结论

干细胞治疗可能改善IUA患者的生殖预后。谨慎推荐通过局部注射自体脂肪或月经血来源的干细胞。需要进一步的大规模随机对照试验来确认长期安全性和最佳治疗方案。

试验注册

该综述方案已在PROSPERO上注册,注册号为CRD42025643871,注册时提供的信息未作修改。

系统评价注册

https://www.crd.york.ac.uk/prospero/,标识符CRD420256438

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验